Study of intensive pediatric pharmacovigilance of nimotuzumab for the treatment of malignant glioma tumors.
Not Applicable
Completed
- Conditions
- Malignant gliomas
- Registration Number
- RPCEC00000183
- Lead Sponsor
- Centro de Inmunología Molecular (CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
1. Children and adolescents between 2 and 19 years of age of btoh gender (male and female)
2. Diagnoses by histology/pathology documented or by images if stem tumor.
3. Life expectancy of at least 4 weeks.
4. Karnofsky / Lansky = 50%.
Exclusion Criteria
1. Participation in another trial.
2. Pregnant or breastfeeding.
3. Decompensated chronic disease.
4. Acute septic processes.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method